<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="editorial"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40400714</article-id><article-id pub-id-type="pmc">PMC12092369</article-id><article-id pub-id-type="publisher-id">1606173</article-id><article-id pub-id-type="doi">10.3389/fphar.2025.1606173</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Editorial</subject></subj-group></subj-group></article-categories><title-group><article-title>Editorial: Identification of effective biomarkers for diagnosis and treatment of chronic kidney disease: integrating bioinformatics and pharmacological approaches</article-title><alt-title alt-title-type="left-running-head">Srivastava and Kanasaki</alt-title><alt-title alt-title-type="right-running-head">
<ext-link xlink:href="https://doi.org/10.3389/fphar.2025.1606173" ext-link-type="uri">10.3389/fphar.2025.1606173</ext-link>
</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Srivastava</surname><given-names>Swayam Prakash</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/781975/overview"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/></contrib><contrib contrib-type="author"><name><surname>Kanasaki</surname><given-names>Keizo</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/63293/overview"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Life Sciences Institute</institution>, <institution>University of Michigan</institution>, <addr-line>Ann Arbor</addr-line>, <addr-line>MI</addr-line>, <country>United States</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Department of Internal Medicine 1</institution>, <institution>Faculty of Medicine</institution>, <institution>Shimane University</institution>, <addr-line>Izumo</addr-line>, <country>Japan</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited and reviewed by:</bold>
<ext-link xlink:href="https://loop.frontiersin.org/people/459226/overview" ext-link-type="uri">Giuseppe Remuzzi</ext-link>, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy</p></fn><corresp id="c001">*Correspondence: Swayam Prakash Srivastava, <email>swayam.cdri@gmail.com</email>, <email>spsr@umich.edu</email>
</corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1606173</elocation-id><history><date date-type="received"><day>04</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>23</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Srivastava and Kanasaki.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Srivastava and Kanasaki</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><related-article related-article-type="commentary-article" id="RA1" xlink:href="https://www.frontiersin.org/research-topics/63666" ext-link-type="uri" journal-id="Front. Pharmacol.">Editorial on the Research Topic <article-title>Identification of effective biomarkers for diagnosis and treatment of chronic kidney disease: integrating bioinformatics and pharmacological approaches</article-title>
</related-article><kwd-group><kwd>chronic kidney disease</kwd><kwd>network phamacology</kwd><kwd>drug-drug interaction</kwd><kwd>molecular docking</kwd><kwd>SGLT-2 inhibitor</kwd><kwd>ANGPTL4</kwd><kwd>AcSDKP</kwd><kwd>sirt3</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that no financial support was received for the research and/or publication of this article.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Renal Pharmacology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Kidney disease affects more than 850 million people globally, and by the year 2040, it is assumed to be the fifth leading cause of mortality. The Global Burden of Disease reports indicate that the prevalence of chronic kidney disease (CKD) increased by 33% worldwide between 1990 and 2017 (<xref rid="B2" ref-type="bibr">Francis et al., 2024</xref>). CKD is a remarkable public health concern worldwide and is associated with increased morbidity, mortality, and healthcare costs. The prevalence of CKD is expected to rise given its association with aging, diabetes, and hypertension. The estimated prevalence of CKD is around 10%&#x02013;14% of the total population, and a great number of people with CKD do not exhibit symptoms until it advances to kidney failure (<xref rid="B4" ref-type="bibr">Kovesdy, 2022</xref>). Chronic kidney disease is a complex kidney disease characterized by impaired renal structure and renal function, persistent inflammation, and moderate immune infiltrations. The consequences of CKD include the irreversible and significant loss of nephrons, tubular damage, chronic immune cell filtrations, reduced regeneration capability, renal macro and microvascular injuries, and aberrant metabolic disarrangements and renal fibrosis, finally leading to kidney failure (<xref rid="B10" ref-type="bibr">Panizo et al., 2021</xref>). Renal fibrosis is a leading cause of death in CKD and contributes to kidney failure (<xref rid="B9" ref-type="bibr">O'Callaghan-Gordo et al., 2019</xref>). Renal fibrosis in CKD is driven by several key signaling pathways, such as inductions of transforming growth factor beta (TGF-&#x003b2;), Wingless/Int-1 (WNT), angiopoietin-like 4 (ANGPTL4), Hedgehog, and NOTCH signaling pathways, dipeptidyl Peptidase-4 (DPP-4)-integrin &#x003b2;1-mediated mechanisms, and mineralocorticoid receptor-related mechanisms. In contrast, protective pathways, such as glucocorticoid receptors, sirtuin 3 (SIRT3), and fibroblast growth factor receptors, suppress the fibrosis process in CKD, (<xref rid="B20" ref-type="bibr">Srivastava et al., 2024</xref>; <xref rid="B12" ref-type="bibr">Srivastava and Goodwin, 2023</xref>; <xref rid="B19" ref-type="bibr">Srivastava et al., 2021a</xref>; <xref rid="B18" ref-type="bibr">Srivastava et al., 2021b</xref>; <xref rid="B5" ref-type="bibr">Li et al., 2020a</xref>; <xref rid="B13" ref-type="bibr">Srivastava et al., 2020a</xref>; <xref rid="B16" ref-type="bibr">Srivastava et al., 2021c</xref>; <xref rid="B1" ref-type="bibr">Bhatia and Srivastava, 2023</xref>).</p><p>Despite the importance of early detection and management of CKD, there is a lack of reliable diagnostic biomarkers and effective therapeutic targets for this condition. This presents a significant clinical challenge to clinicians and researchers. Therefore, there is an urgent need to explore new strategies for the diagnosis and management of CKD. Several therapeutic agents are being evaluated for their efficacy in preclinical models. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown significant antifibrotic effects in mouse models by inhibiting the partial epithelial-mesenchymal transition (EMT) and restoring kidney structure and function (<xref rid="B6" ref-type="bibr">Li et al., 2020b</xref>). Empagliflozin is a drug belonging to the class of SGLT-2 inhibitors, and it has been shown to induce mitochondrial protein SIRT3 levels and elevate the levels of fatty acid oxidation; these mechanisms are found to be suppressed in injured kidneys (<xref rid="B6" ref-type="bibr">Li et al., 2020b</xref>). Concomitantly, empagliflozin significantly suppressed the abnormal glycolysis and related kidney fibrosis in a mouse model of CKD (<xref rid="B6" ref-type="bibr">Li et al., 2020b</xref>). This aberrant glycolysis mediated through pyruvate kinase M2 type dimers and hypoxia inducible factor 1a (HIF-1a) is the causative mechanism for the development of CKD (<xref rid="B6" ref-type="bibr">Li et al., 2020b</xref>; <xref rid="B17" ref-type="bibr">Srivastava et al., 2018</xref>). SIRT3 activation agents, such as honokiol and 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR), have shown protective effects against CKD (<xref rid="B21" ref-type="bibr">Wei et al., 2023</xref>). Linagliptin, a DPP-4 inhibitor, exhibits reno-protective effects beyond diabetes (<xref rid="B13" ref-type="bibr">Srivastava et al., 2020a</xref>; <xref rid="B3" ref-type="bibr">Kanasaki et al., 2014</xref>; <xref rid="B11" ref-type="bibr">Shi et al., 2015</xref>). In addition, linagliptin inhibited partial EMT and endothelial-to-mesenchymal transition (EndMT) by suppressing hypoxia-related proteins and Snail and Twist levels. Rho-associated protein kinase 2 (ROCK2)-TGF-&#x003b2;1-EMT and ROCK2-nuclear factor erythroid 2-related factor 2 (Nrf2) pathways may offer a novel therapeutic strategy for the treatment of CKD (<xref rid="B22" ref-type="bibr">You et al., 2020</xref>). However, a large cohort clinical trial is needed to analyze its effects in human subjects. Conventional treatment involves reno-protective agents such as angiotensin converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs), and both classes of drugs lower the hypertension-related fibrogenesis in the kidney (<xref rid="B7" ref-type="bibr">Nagai et al., 2014</xref>; <xref rid="B8" ref-type="bibr">Nitta et al., 2016</xref>). AcSDKP has been found to be effective in lowering the late-stage fibrosis in mouse models of CKD by elevating SIRT3 protein levels and improving mitochondrial function in tubules, podocytes, and endothelial cells (<xref rid="B14" ref-type="bibr">Srivastava et al., 2020b</xref>; <xref rid="B15" ref-type="bibr">Srivastava et al., 2020c</xref>).</p><p>The one-drug/one-target/one-disease approach to drug discovery is presently facing many challenges of safety, efficacy, and sustainability. Today, network pharmacology and molecular docking are the most utilized system biology approaches and are used in drug discovery to study the mechanism of action of small-molecule entities or natural products in the management of CKD. These techniques help us identify therapeutic targets, understand drug-drug interactions, and predict the interventions on the complex signaling pathways related to CKD progression. Combining network pharmacology and molecular docking provides a comprehensive approach to identifying potential therapeutic options and offers a promising approach for identifying effective biomarkers for CKD. Integrated analyses of data from various sources, such as next-generation sequencing analysis, single-cell transcriptomic and single-cell genomics analysis, and microarray and metabolomics data, can provide a comprehensive overview of the molecular changes associated with CKD. Metabolomics can be utilized to screen differentially expressed metabolites in kidney tissues and to predict potential targets using relevant databases. The interaction networks among endogenous metabolites and target proteins have been established by integrating differentially expressed metabolites and proteins associated with CKD identified through proteomics. Bioinformatics analyses such as gene ontology (GO) analysis, Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis, and weighted gene co-expression network analysis (WGCNA) can identify key signaling pathways and potential biomarkers associated with CKD development and progression. Pharmacological approaches can provide additional insights through the analysis of drug&#x02013;gene interactions and the identification of potential therapeutic targets for CKD. The biological functions of the candidate metabolites and their effects on downstream pathways can be verified. <xref rid="F1" ref-type="fig">Figure 1</xref> demonstrates the schematic chart for the target identification and drug screening against CKD.</p><fig position="float" id="F1"><label>FIGURE 1</label><caption><p>A schematic diagram showing the use of network pharmacology, drug-drug interactions in <italic>in vitro</italic> and <italic>in vivo</italic> screening. Components of this figure were created using Servier Medical Art templates, which are licensed under a Creative Commons Attribution 3.0 Unported License; <ext-link xlink:href="https://smart.servier.com" ext-link-type="uri">https://smart.servier.com</ext-link>.</p></caption><graphic xlink:href="fphar-16-1606173-g001" position="float"/></fig><p>This article Research Topic aims to 1) identify effective biomarkers for the diagnosis and treatment of CKD by integrating bioinformatics and pharmacological approaches; 2) conduct bioinformatics analyses, including GO analysis, KEGG pathway analysis, and WGCNA, to identify key signaling pathways and potential biomarkers; 3) explore potential pharmacological implications by analyzing drug-gene interactions and identify potential therapeutic targets; and 4) examine immune infiltration features and related hub genes that might play a role in CKD development.</p><p>In this Research Topic, <ext-link xlink:href="https://doi.org/10.3389/fphar.2025.1480732" ext-link-type="uri">Patil et al.</ext-link> elucidate the disulfiram-modulated targets and pathways in renal fibrosis. The authors have analyzed the protein&#x02013;protein interactions, pathway enrichment, and cluster and gene ontology between disulfiram and renal fibrosis by using the molecular docking procedure. Moreover, molecular dynamics simulation was performed to infer protein&#x02013;ligand stability, and conformational changes were analyzed by free energy landscape. This analysis determines the renal protective activity of disulfiram and paves the way for experimental investigation to repurpose disulfiram for treating renal fibrosis. Another manuscript by <ext-link xlink:href="https://doi.org/10.3389/fendo.2025.1416506" ext-link-type="uri">Huang et al.</ext-link> investigates the correlation between hemoglobin A1c (HbA1c) levels and all-cause and cardiovascular disease mortality in elderly individuals with non-diabetic CKD.</p><p>In conclusion, a better understanding of these interactions can inform the development of targeted therapies that can improve the diagnosis and management of CKD.</p></body><back><sec sec-type="author-contributions" id="s1"><title>Author contributions</title><p>SS: Investigation, Supervision, Writing &#x02013; review and editing, Funding acquisition, Software, Writing &#x02013; original draft, Resources, Visualization, Conceptualization. KK: Writing &#x02013; review and editing, Funding acquisition.</p></sec><sec sec-type="COI-statement" id="s3"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p><p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p></sec><sec sec-type="ai-statement" id="s4"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s5"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhatia</surname><given-names>D.</given-names></name><name><surname>Srivastava</surname><given-names>S. P.</given-names></name></person-group> (<year>2023</year>). <article-title>Editorial: diabetic kidney disease: routes to drug development, pharmacology and underlying molecular mechanisms</article-title>. <source>Front. Pharmacol.</source>
<volume>14</volume>, <fpage>1252315</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2023.1252315</pub-id>
<pub-id pub-id-type="pmid">37614315</pub-id>
</mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Francis</surname><given-names>A.</given-names></name><name><surname>Harhay</surname><given-names>M. N.</given-names></name><name><surname>Ong</surname><given-names>A. C. M.</given-names></name><name><surname>Tummalapalli</surname><given-names>S. L.</given-names></name><name><surname>Ortiz</surname><given-names>A.</given-names></name><name><surname>Fogo</surname><given-names>A. B.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Chronic kidney disease and the global public health agenda: an international consensus</article-title>. <source>Nat. Rev. Nephrol.</source>
<volume>20</volume>, <fpage>473</fpage>&#x02013;<lpage>485</lpage>. <pub-id pub-id-type="doi">10.1038/s41581-024-00820-6</pub-id>
<pub-id pub-id-type="pmid">38570631</pub-id>
</mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kanasaki</surname><given-names>K.</given-names></name><name><surname>Shi</surname><given-names>S.</given-names></name><name><surname>Kanasaki</surname><given-names>M.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Nagai</surname><given-names>T.</given-names></name><name><surname>Nakamura</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen</article-title>. <source>Diabetes</source>
<volume>63</volume>, <fpage>2120</fpage>&#x02013;<lpage>2131</lpage>. <pub-id pub-id-type="doi">10.2337/db13-1029</pub-id>
<pub-id pub-id-type="pmid">24574044</pub-id>
</mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kovesdy</surname><given-names>C. P.</given-names></name></person-group> (<year>2022</year>). <article-title>Epidemiology of chronic kidney disease: an update 2022</article-title>. <source>Kidney Int. Suppl. (2011)</source>
<volume>12</volume>, <fpage>7</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.kisu.2021.11.003</pub-id>
<pub-id pub-id-type="pmid">35529086</pub-id>
</mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Srivastava</surname><given-names>S. P.</given-names></name><name><surname>Hu</surname><given-names>Q.</given-names></name><name><surname>Gao</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>Endothelial FGFR1 (fibroblast growth factor receptor 1) deficiency contributes differential fibrogenic effects in kidney and heart of diabetic mice</article-title>. <source>Hypertension</source>
<volume>76</volume>, <fpage>1935</fpage>&#x02013;<lpage>1944</lpage>. <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.120.15587</pub-id>
<pub-id pub-id-type="pmid">33131311</pub-id>
</mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Takagi</surname><given-names>S.</given-names></name><name><surname>Nitta</surname><given-names>K.</given-names></name><name><surname>Kitada</surname><given-names>M.</given-names></name><name><surname>Srivastava</surname><given-names>S. P.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules</article-title>. <source>JCI Insight</source>
<volume>5</volume>, <fpage>e129034</fpage>. <pub-id pub-id-type="doi">10.1172/jci.insight.129034</pub-id>
<pub-id pub-id-type="pmid">32134397</pub-id>
</mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nagai</surname><given-names>T.</given-names></name><name><surname>Kanasaki</surname><given-names>M.</given-names></name><name><surname>Srivastava</surname><given-names>S. P.</given-names></name><name><surname>Nakamura</surname><given-names>Y.</given-names></name><name><surname>Ishigaki</surname><given-names>Y.</given-names></name><name><surname>Kitada</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>N-acetyl-seryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-mesenchymal transition</article-title>. <source>Biomed. Res. Int.</source>
<volume>2014</volume>, <fpage>696475</fpage>. <pub-id pub-id-type="doi">10.1155/2014/696475</pub-id>
<pub-id pub-id-type="pmid">24783220</pub-id>
</mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nitta</surname><given-names>K.</given-names></name><name><surname>Shi</surname><given-names>S.</given-names></name><name><surname>Nagai</surname><given-names>T.</given-names></name><name><surname>Kanasaki</surname><given-names>M.</given-names></name><name><surname>Kitada</surname><given-names>M.</given-names></name><name><surname>Srivastava</surname><given-names>S. P.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Oral administration of N-Acetyl-seryl-aspartyl-lysyl-proline ameliorates kidney disease in both type 1 and type 2 diabetic mice via a therapeutic regimen</article-title>. <source>Biomed. Res. Int.</source>
<volume>2016</volume>, <fpage>9172157</fpage>. <pub-id pub-id-type="doi">10.1155/2016/9172157</pub-id>
<pub-id pub-id-type="pmid">27088094</pub-id>
</mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O'Callaghan-Gordo</surname><given-names>C.</given-names></name><name><surname>Shivashankar</surname><given-names>R.</given-names></name><name><surname>Anand</surname><given-names>S.</given-names></name><name><surname>Ghosh</surname><given-names>S.</given-names></name><name><surname>Glaser</surname><given-names>J.</given-names></name><name><surname>Gupta</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Prevalence of and risk factors for chronic kidney disease of unknown aetiology in India: secondary data analysis of three population-based cross-sectional studies</article-title>. <source>BMJ Open</source>
<volume>9</volume>, <fpage>e023353</fpage>. <pub-id pub-id-type="doi">10.1136/bmjopen-2018-023353</pub-id>
</mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Panizo</surname><given-names>S.</given-names></name><name><surname>Mart&#x000ed;nez-Arias</surname><given-names>L.</given-names></name><name><surname>Alonso-Montes</surname><given-names>C.</given-names></name><name><surname>Cannata</surname><given-names>P.</given-names></name><name><surname>Mart&#x000ed;n-Carro</surname><given-names>B.</given-names></name><name><surname>Fern&#x000e1;ndez-Mart&#x000ed;n</surname><given-names>J. L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Fibrosis in chronic kidney disease: pathogenesis and consequences</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>22</volume>, <fpage>408</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22010408</pub-id>
<pub-id pub-id-type="pmid">33401711</pub-id>
</mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shi</surname><given-names>S.</given-names></name><name><surname>Srivastava</surname><given-names>S. P.</given-names></name><name><surname>Kanasaki</surname><given-names>M.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Kitada</surname><given-names>M.</given-names></name><name><surname>Nagai</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Interactions of DPP-4 and integrin &#x003b2;1 influences endothelial-to-mesenchymal transition</article-title>. <source>Kidney Int.</source>
<volume>88</volume>, <fpage>479</fpage>&#x02013;<lpage>489</lpage>. <pub-id pub-id-type="doi">10.1038/ki.2015.103</pub-id>
<pub-id pub-id-type="pmid">25830763</pub-id>
</mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>S. P.</given-names></name><name><surname>Goodwin</surname><given-names>J. E.</given-names></name></person-group> (<year>2023</year>). <article-title>Loss of endothelial glucocorticoid receptor accelerates organ fibrosis in db/db mice</article-title>. <source>Am. J. Physiol. Ren. Physiol.</source>
<volume>325</volume>, <fpage>F519</fpage>&#x02013;<lpage>F526</lpage>. <pub-id pub-id-type="doi">10.1152/ajprenal.00105.2023</pub-id>
</mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>S. P.</given-names></name><name><surname>Goodwin</surname><given-names>J. E.</given-names></name><name><surname>Kanasaki</surname><given-names>K.</given-names></name><name><surname>Koya</surname><given-names>D.</given-names></name></person-group> (<year>2020a</year>). <article-title>Inhibition of angiotensin-converting enzyme ameliorates renal fibrosis by mitigating DPP-4 level and restoring antifibrotic MicroRNAs</article-title>. <source>Genes (Basel)</source>
<volume>11</volume>, <fpage>211</fpage>. <pub-id pub-id-type="doi">10.3390/genes11020211</pub-id>
<pub-id pub-id-type="pmid">32085655</pub-id>
</mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>S. P.</given-names></name><name><surname>Goodwin</surname><given-names>J. E.</given-names></name><name><surname>Kanasaki</surname><given-names>K.</given-names></name><name><surname>Koya</surname><given-names>D.</given-names></name></person-group> (<year>2020b</year>). <article-title>Metabolic reprogramming by N-acetyl-seryl-aspartyl-lysyl-proline protects against diabetic kidney disease</article-title>. <source>Br. J. Pharmacol.</source>
<volume>177</volume>, <fpage>3691</fpage>&#x02013;<lpage>3711</lpage>. <pub-id pub-id-type="doi">10.1111/bph.15087</pub-id>
<pub-id pub-id-type="pmid">32352559</pub-id>
</mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>S. P.</given-names></name><name><surname>Kanasaki</surname><given-names>K.</given-names></name><name><surname>Goodwin</surname><given-names>J. E.</given-names></name></person-group> (<year>2020c</year>). <article-title>Loss of mitochondrial control impacts renal health</article-title>. <source>Front. Pharmacol.</source>
<volume>11</volume>, <fpage>543973</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.543973</pub-id>
<pub-id pub-id-type="pmid">33362536</pub-id>
</mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>S. P.</given-names></name><name><surname>Kanasaki</surname><given-names>K.</given-names></name><name><surname>Goodwin</surname><given-names>J. E.</given-names></name></person-group> (<year>2021c</year>). <article-title>Editorial: combating diabetes and diabetic kidney disease</article-title>. <source>Front. Pharmacol.</source>
<volume>12</volume>, <fpage>716029</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.716029</pub-id>
<pub-id pub-id-type="pmid">34305620</pub-id>
</mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>S. P.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Kitada</surname><given-names>M.</given-names></name><name><surname>Fujita</surname><given-names>H.</given-names></name><name><surname>Yamada</surname><given-names>Y.</given-names></name><name><surname>Goodwin</surname><given-names>J. E.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>SIRT3 deficiency leads to induction of abnormal glycolysis in diabetic kidney with fibrosis</article-title>. <source>Cell Death Dis.</source>
<volume>9</volume>, <fpage>997</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-018-1057-0</pub-id>
<pub-id pub-id-type="pmid">30250024</pub-id>
</mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>S. P.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Takagaki</surname><given-names>Y.</given-names></name><name><surname>Kitada</surname><given-names>M.</given-names></name><name><surname>Goodwin</surname><given-names>J. E.</given-names></name><name><surname>Kanasaki</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2021b</year>). <article-title>Endothelial SIRT3 regulates myofibroblast metabolic shifts in diabetic kidneys</article-title>. <source>iScience</source>
<volume>24</volume>, <fpage>102390</fpage>. <pub-id pub-id-type="doi">10.1016/j.isci.2021.102390</pub-id>
<pub-id pub-id-type="pmid">33981977</pub-id>
</mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>S. P.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Setia</surname><given-names>O.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Kanasaki</surname><given-names>K.</given-names></name><name><surname>Koya</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2021a</year>). <article-title>Loss of endothelial glucocorticoid receptor accelerates diabetic nephropathy</article-title>. <source>Nat. Commun.</source>
<volume>12</volume>, <fpage>2368</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-021-22617-y</pub-id>
<pub-id pub-id-type="pmid">33888696</pub-id>
</mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>S. P.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Shenoi</surname><given-names>R.</given-names></name><name><surname>Morris</surname><given-names>M.</given-names></name><name><surname>Lainez-Mas</surname><given-names>B.</given-names></name><name><surname>Goedeke</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Renal Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease</article-title>. <source>Sci. Adv.</source>
<volume>10</volume>, <fpage>eadn6068</fpage>. <pub-id pub-id-type="doi">10.1126/sciadv.adn6068</pub-id>
<pub-id pub-id-type="pmid">39630889</pub-id>
</mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wei</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Lao</surname><given-names>Y.</given-names></name><name><surname>Weng</surname><given-names>J.</given-names></name><name><surname>Deng</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Effects of honokiol protects against chronic kidney disease via BNIP3/NIX and FUNDC1-mediated mitophagy and AMPK pathways</article-title>. <source>Mol. Biol. Rep.</source>
<volume>50</volume>, <fpage>6557</fpage>&#x02013;<lpage>6568</lpage>. <pub-id pub-id-type="doi">10.1007/s11033-023-08592-1</pub-id>
<pub-id pub-id-type="pmid">37338733</pub-id>
</mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>You</surname><given-names>R.</given-names></name><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Jia</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Inhibition of ROCK2 alleviates renal fibrosis and the metabolic disorders in the proximal tubular epithelial cells</article-title>. <source>Clin. Sci. (Lond)</source>
<volume>134</volume>, <fpage>1357</fpage>&#x02013;<lpage>1376</lpage>. <pub-id pub-id-type="doi">10.1042/CS20200030</pub-id>
<pub-id pub-id-type="pmid">32490513</pub-id>
</mixed-citation></ref></ref-list></back></article>